Added to YB: 2026-10-08
Pitch date: 2026-10-04
CABA [bullish]
Cabaletta Bio, Inc.
-22.89%
current return
Author Info
No bio for this author
Company Info
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Market Cap
$352.7M
Pitch Price
$2.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.85
P/E
-1.35
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Cabaletta Bio, Inc.
CABA (quick overview): Cabaletta is a longer-dated autoimmune cell-therapy thesis centered on rese-cel, a CD19 CAR-T designed to deliver a one-time immune reset in diseases including lupus, myositis and systemic sclerosis. The key trigger is a pivotal or registration-directed program with clean efficacy, safety, manufacturing and durability — not a near-term acquisition rumor — while logistics, lymphodepletion, reimbursement and durability could still limit adoption even if the biology works.
Read full article (1 min)